Evaluating Health-Related Quality of Life (HRQoL) in Patients with and without Crohn?s Perianal Fistulas (CPF) Using the Euroqol Five-Dimension (EQ-5D-5L) Questionnaire in a Real-World US Setting
Jiang J1, Nazarey P2, Kuharic M2, Athavale A3, Fan T2, Silber A4, Abilash V3, Hadker N3, Sharpe E3, Cazzetta S2
1Takeda Pharmaceuticals USA, Inc., Cambridge, MA, USA, 2Takeda Pharmaceuticals USA, Inc., Lexington, MA, USA, 3Trinity Life Sciences, Waltham, MA, USA, 4Trinity Partners, LLC, Waltham, MA, USA
OBJECTIVES: Crohn’s disease (CD) substantially impacts HRQoL, with complications such as perianal fistulas potentially increasing burden of illness. We investigated HRQoL in patients with CD and CPF and those without CPF, and for patients with CPF with and without CPF-related surgery. METHODS: Data were collected via cross-sectional, web-enabled questionnaires for three US patient cohorts aged 18–89 years with self-reported physician-diagnosed CD: (1) without CPF, with CPF (2) without CPF-related surgery and (3) with CPF-related surgery. HRQoL assessment used the EQ-5D-5L questionnaire (comprising a five-dimension profile: mobility, self-care, usual activities, pain/discomfort, anxiety/depression; and the visual analogue scale [EQ-VAS; scored 0–100, higher values reflecting increased HRQoL]). Health state index scores were calculated using the US value set (scores range from <0–1), with greater scores indicating higher health utility. Data were summarized using descriptive statistics (significance reported at 0.05). RESULTS: Overall, 403 patients were analyzed (cohort 1, n=300 [mean (standard deviation) age, 47 (16.4) years]; cohort 2, n=51 [40 (12.2) years]; cohort 3, n=52 [39 (13.1) years]). Patients with CPF reported lower mean overall index scores than those without (0.69 [cohort 1] versus 0.57 [cohort 2] and 0.55 [cohort 3]; both p<0.01), and lower scores across all five EQ-5D-5L dimensions, especially anxiety/depression (p≤0.01). Mean EQ-VAS scores did not significantly differ, although cohort 3 scored lower (59.5) than cohorts 1 (64.6) and 2 (63.1). Mean cohort utility scores were lower than for the overall US population (0.85) and other diseases (0.79 [diabetes]; 0.71 [depression]). CONCLUSIONS: Real-world patients with CD and CPF report worse utility and EQ-VAS scores than those without CPF, the US general population or for other diseases. These data demonstrate that CPF-related surgery did not increase HRQoL, highlighting a need for improved disease management, and may aid future economic model development. Study sponsor: Takeda Pharmaceuticals USA, Inc.
Conference/Value in Health Info
2021-05, ISPOR 2021, Montreal, Canada
Value in Health, Volume 24, Issue 5, S1 (May 2021)
Health State Utilities